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Background: Although many studies have indicated that high-mobility group box 1 protein (HMGB1) is associated
with oncogenesis and a worse prognosis, the prognostic value of HMGB1 in gastric cancer (GC) remains unclear. In
the present work, we aimed to evaluate the role of HMGB1 in GC and examined whether aberrant expression of
both HMGB1 and vascular endothelial growth factor C (VEGF-C) increased the malignant potential of GC.
Methods: A total of 166 GC patients and 32 normal subjects were enrolled. HMGB1 and VEGF-C expression was detected
by tissue microarrays (TMAs) and immunohistochemical staining. The correlation between HMGB1 and VEGF-C expression
and their relationships with clinicopathological GC variables were examined. Univariate and multivariate analyses were
performed using the Cox proportional hazard model to predict the factors related to the patients‘ overall survival rates.
Results: HMGB1 and VEGF-C expression were observed in 81 (48.80%) and 88 (53.01%) tumors, respectively,
significantly higher than the rates among the corresponding controls. In addition, HMGB1 and VEGF-C expression were
positively correlated (R2 = 0.972). HMGB1 expression was also closely associated with tumor size, pT stage, nodal status,
metastasis status, TNM stage, and poor prognosis. Multivariate survival analysis indicated that patients with HMGB1 and
VEGF-C coexpression had the worst prognoses and survival rates (hazard ratio, 2.78; log rank P<0.001).
Conclusions: HMGB1 is commonly expressed in GC. Combined evaluation of HMGB1 and VEGF-C may serve as a
valuable independent prognostic factor for GC patients.
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Gastric cancer (GC) is a highly malignant disease with a
poor prognosis, and is the second most common cause of
cancer-related death worldwide. GC tends to be associated
with hematogenous metastasis, peritoneal dissemination,
and lymph node metastasis. For patients with advanced
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reproduction in any medium, provided the orMultiple steps and factors involved in tumorigenesis, tumor
invasion, and metastasis of GC influence disease prognosis,
particularly metastatic dissemination of the primary tumor.
However, the mechanisms of metastasis remain elusive.
The identification of a predictive marker to evaluate the
behavior of tumor development and metastasis would be
valuable in clinical practice.
High-mobility group box 1 protein (HMGB1), also known
as amphoterin, is a relatively small, versatile protein of
215 amino acid residues. Originally characterized as a
non-histone nuclear-DNA-binding protein, HMGB1 can
stabilize the structure and function of chromatin and
regulate gene transcription [1,2]. It is also present in the
cytoplasm and stroma cells and can be associated withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and chemotherapeutic response [3]. Overexpression and
cytoplasmic localization of HMGB1 is associated with
the proliferation and metastasis of many tumor types,
particularly in conjunction with the receptor for advanced
glycation end products (RAGEs) [4,5]. Increased expression
of HMGB1 occurs in many solid tumors, including
breast cancer [6], gastric cancer [7,8], colon cancer [9,10],
and nasopharyngeal carcinoma [11]. Its aberrant expression
is usually associated with the proliferation and metastasis of
tumors and a worse prognosis [8-12]. Although serum
levels of HMGB1 have been shown to be a useful marker to
predict poor prognosis in GC [13], another study reported
that overexpression of HMGB1 was positively correlated
with cancer-free survival of resectable gastric adenocarcin-
omas [7]. Therefore, detailed studies with consecutive and
extensive sample numbers are needed to confirm the
clinical value of HMGB1 as a prognostic factor in GC.
Vascular endothelial growth factor C (VEGF-C) is a
specific growth factor that targets the lymphatic systemFigure 1 Immunohistochemical labeling of vascular endothelial grow
primary gastric cancer (GC) and normal gastric tissue. Tissue microarra
was significantly increased in GC tissues. HMGB1 was mainly localized to th
effusive to the cytoplasm and stroma in some cases (D). The cytoplasmic e
samples (E), yielded similar results (F). Bar, 50 μm.and plays a critical role in tumor growth and metastasis to
lymph nodes and distant organs through the formation
of new vessels in various malignancies, including GC
[14-16]. HMGB1 was previously reported to enhance the
invasion ability of tumor cells through a VEGF-C-related
pathway [17], and HMGB1 promotes lymphangiogenesis
in human lymphatic endothelial cells [18]. Thus, we
have attempted to determine if HMGB1 promotes tumor
metastasis by upregulating the expression of VEGF-C or if
each protein exerts its function independently. Because
simultaneous expression of HMGB1 and VEGF-C has
not been examined in a well-characterized series of GCs
with long-term follow-up, the present study serves
to re-evaluate the application of HMGB1 and VEGF-C
expression as a prognostic predictor in GC.
Methods
Patients
A total of 166 consecutive patients with gastric cancer
who underwent gastrectomy at the Department ofth factor C (VEGF-C) and high-mobility group box 1 (HMGB1) in
ys of GC and non-gastric carcinoma tissue are shown (A,B). HMGB1
e nucleus but,when compared to the normal gastric tissue (C), was
xpression of VEGF-C,when compared to the negative corresponding
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ated Hospital of Sun Yat-Sen University from 2003 to 2005
were included in the present study. Patients who received
chemotherapy, radiotherapy, and/or biotherapy before
surgery were excluded from the study. The pathologic stage
of the disease was determined according to the American
Joint Committee on Cancer (AJCC) TNM staging system.
All treatment plans were designed according to the latest
National Comprehensive Cancer Network (NCCN) guide-
lines for GC. In the group, 139 patients received radical
operations with neither gross nor microscopic evidence of
residual disease, and these patients were included in theTable 1 Association between the expression of vascular endo





Total 166 81 85 48.80
Age at surgery:
<60 84 45 39 53.57
≥60 82 36 46 43.90
Gender:
Male 113 59 54 52.21
Female 53 22 31 41.51
Histological type:
Adenocarcinoma 135 62 73 45.93
Other 31 19 12 61.29
Tumor size:
<4 cm 83 30 53 36.14
≥4 cm 83 51 32 61.45
Borrmann type:
I+II 35 16 19 45.71
III+IV 131 65 66 49.62
Differentiation:
Low 113 56 57 49.56
Moderate andhigh 53 25 28 43.24
pT stage:
pT1 to pT2 34 9 25 26.47
pT3 to pT4 132 72 60 54.55
Distant metastasis:
M0 122 53 69 43.44
M1 44 28 16 63.64
TNM stage:
Stage I+II 61 17 44 27.87
Stage III+IV 105 64 41 60.95
Nodal status:
pN0 63 19 44 30.16
pN1 to pN3 103 62 41 60.19survival and prognostic analyses. Overall survival was
defined as the length of time from surgery to death or to the
last follow-up in the chosen patients. Normal subjects
included non-gastric cancer cases excluded by histopathology
under a gastroscope. The use of tissue samples for tissue
microarray (TMA) analyses and clinical data were approved
by the Medical Ethics Committee of the First Affiliated
Hospital of Sun Yat-Sen University and the patients.
Tissue array construction and immunohistochemical staining
Cores of 1 mm were removed from formalin-fixed paraffin-
embedded samples of GC and adjacent normal gastricthelial growth factor C (VEGF-C) and high-mobility group








0.213 47 37 55.95 0.442
41 41 50.00
0.198 59 54 55.66 0.763
29 24 59.18
0.123 69 66 51.11 0.306
19 12 61.29
0.001 32 51 38.55 <0.001
56 27 67.47
0.681 17 18 48.57 0.553
71 60 54.20
0.774 58 55 51.33 0.525
30 23 54.05
0.003 10 24 29.41 0.002
78 54 59.09
0.022 57 65 46.72 0.007
31 13 70.45
<0.001 17 44 27.87 <0.001
71 34 67.62
<0.001 21 42 33.33 <0.001
67 36 65.05
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areas of the tumor were removed for each case and were
placed into a new blank recipient paraffin block as previously
described by Hsu et al. [19], and 4-μm thick sections were
taken for immunohistochemistry. Immunohistochemical
staining for HMGB1 and VEGF-C was performed according
to protocols available at http://www.abcam.com/index.html?
pageconfig=popular_protocols. Samples were subsequently
incubated with anti-HMGB1 (1:100, Santa Cruz Biotechno-
logy, Santa Cruz, CA, USA) or anti-VEGF-C antibody
(1:100, Santa Cruz) and visualized with an Envision Chem
Detection Kit (Dako Cytomation, Carpinteria, CA, USA).
Histological and immunohistochemical assessment
All slides were coded and evaluated blindly by two inde-
pendent experienced pathologists. The final values of theFigure 2 Correlation between vascular endothelial growth factor C (V
coefficient revealed that VEGF-C expression was highly correlated with HM
human recombinant HMGB1 (hrHMGB1) for 24 h, and the cultured medium
secretion was not significantly upregulated by HMGB1 in a dose-dependenpositive tumor cells were assessed as the mean value of
the immunoreactivity of five randomly selected areas of
each section for correlation and confirmation of the
tissue analysis. VEGF-C immunoreactivity was defined as
a cytoplasmic staining pattern and HMGB1 as a nuclear
staining pattern with or without cytoplasmic staining.
Scores of the positive ratios were evaluated according to a
previous report [7] as follows: score 0, <5%; score 1, 5% to
24%; score 2, 25% to 49%; score 3, 50%to 100%. For the
purpose of statistical analysis, we combined samples with
scores of 0 and 1 to represent negative expression and
scores of 2 and 3 to represent positive expression.
Cell lines
The immortalized human gastric epithelial mucosa cell line
GES-1 and three human GC cell lines (MGC803, AGS andEGF-C) and high-mobility group box 1 (HMGB1). A correlation
GB1 in gastric cancer (GC) (A). In vitro, cells were incubated with
was then used to determine the VEGF-C concentration. VEGF-C
t manner in GES-1 cells (B),but was in GC cells (C).
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Type Culture Collection of the Chinese Academy of
Sciences (Shanghai, China) and passaged in our laboratory
for less than 6 months after receipt. GES-1 was cultured in
Dulbecco’s Modified Eagle Medium (DMEM; Gibco,
Carlsbad, CA, USA), and GC cell lines were cultured in
RPMI 1640 medium (Gibco, Carlsbad, CA, USA) sup-
plemented with 10% fetal calf serum (HyClone, Logan,
UT, USA) at 37°C in a humidified atmosphere of 5% CO2.
Preparation of conditioned medium
To determine the effect of HMGB1 on VEGF-C expression,
cell culture media was analyzed with a VEGF-C ELISA Kit
(R&D Systems, Minneapolis, MN, USA). Briefly, 1×104
cultured cells were incubated with human recombinant
HMGB1 (hrHMGB1, Sigma, St. Louis, MO, USA) for 24 h.
Then, the cultured medium was filtered with a 0.2-μm push
filter (Millipore, MA, USA) and analyzed by ELISA [17,20].
Statistical analysis
Statistical analysis was performed using the statistical
software package SPSS 16.0 (SPSS Inc., Chicago, IL,
USA). The associations between HMGB1 and VEGF-C
expression and clinicopathological parameters were
assessed. To identify the independent factors that may
be significantly related to patient prognosis, univariateFigure 3 Kaplan-Meier plots for the cumulative 5-year survival of pat
according to high-mobility group box 1 (HMGB1)expression status. P
poorer prognosis than other patients (P<0.001, log-rank test).analysis and multivariate survival analyses were performed
using a Cox proportional hazard model. The survival rates
of patients with different HMGB1 or VEGF-C expression
status were analyzed by the Kaplan-Meier method, and
the survival curves were stratified according to HMGB1
and VEGF-C expression status by the log-rank test. All
tests were two-sided, and P values of less than 0.05 were
considered statistically significant.Results
Expression of HMGB1 and VEGF-C proteins in GC
HMGB1 protein expression was evaluated by immuno-
histochemical staining. As a non-histone DNA binding
protein, the expression of HMGB1 protein was mainly
localized to the nucleus but was also effusive in the cyto-
plasm and the stroma in some cases (Figure 1D). Positive
staining was detected in 81/166 (48.80%) GC cells and
5/32 (15.6%) in non-cancerous cells. The difference in
these staining patterns was statistically significant (P<0.05;
Figure 1C). VEGF-C was observed almost exclusively
in the cytoplasm of gastric tumor cells, as previously
reported [17,20] (Figure 1F). The positive rate of VEGF-C
staining in the primary tumor was 53.01%, and no positive
staining was observed in non-cancerous gastric tissues
(P<0.05, Figure 1E).ients with gastric cancer (GC) after radical resection, stratified
atients with tumors strongly positive for HMGB1 had significantly
Table 2 Cox regression survival analysis of factors










I and II 1
III and IV 0.78 0.21 2.85 0.7072
Histologic differentiation:
Well and moderate 1
Poorly 1.26 0.67 2.38 0.4756
Tumor size:
<4 cm 1
≥4 cm 1.17 0.63 2.18 0.6277
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clinicopathological characteristics
The relationship between HMGB1, VEGF-C expression,
and various clinicopathological features (tumor size, pT
stage, distant metastasis, nodal status, and TNM stage)
was analyzed (Table 1). The expression of HMGB1 was
significantly correlated with tumor size, pT stage, lymph
node metastasis, and TNM stage (Table 1) but not with
age, gender, pathological type, or tumor differentiation.
Meanwhile, VEGF-C expression displayed associations
with clinicopathological characteristics similar to those of
HMGB1 (Table 1). In addition, statistical analysis demon-
strated that there was a significant correlation between
HMGB1 and VEGF-C expression (Figure 2A, R2 = 0.972,
P<0.01).pT stage:
pT1 and pT2 1
pT3 and pT4 1.99 0.60 6.60 0.2595
Lymph node metastasis:
Absence 1
Presence 2.58 1.01 5.06 0.0480
TNM stage:
I, II 1
III, IV 2.70 1.06 7.03 0.0296HMGB1 upregulates VEGF-C secretion in GC cell lines
To further evaluate the effects of HMGB1 on VEGF-C, we
treated GES-1 and GC cells with hrHMGB1. VEGF-C
secretion was remarkably increased by incubation with
hrHMGB1 in a dose-dependent manner in GC cells
(Figure 2C) but not in GES-1 cells (Figure 2B). These
data support the correlation between HMGB1 and
VEGF-C in vivo.High-mobility group box 1
(HMGB1)expression:
Negative 1
Positive 2.66 1.04 6.32 0.0370
Vascular endothelial growth
factor C (VEGF-C) expression:
Negative 1





2.78 1.21 6.40 0.0162
aOthers were HMGB1 negative and VEGF-C negative, HMGB1 negative and
VEGF-C positive, and HMGB1 positive and VEGF-C negative.Prognostic value of HMGB1 and VEGF-C expression in GC
patients
Because HMGB1 and VEGF-C expression were both
significantly associated with tumor invasion and metastasis
in GC (Table 1), we further investigated whether these
two immunohistochemical markers could be used as
prognostic predictors for GC. A total of 139 patients who
received radical operations with standard D2 or extended
lymph node dissection were included in the prognostic
analysis. Univariate analysis revealed that tumor size, pT
stage, lymph node metastasis, TNM stage, histological
differentiation, HMGB1 expression, and VEGF-C expres-
sion were all significantly associated with poor survival
rates (data not shown). As expected, patients with positive
HMGB1 staining (+) had a much poorer prognosis
than those with negative HMGB1 (−) staining (Figure 3).
Furthermore, Cox’s multivariate analysis revealed that
lymph node metastasis, TNM stage, HMGB1 expression,
VEGF-C expression, and combined HMGB1/VEGF-C
expression were significant predictors of survival (Table 2).
Survival curves plotted according to the Kaplan-Meier
method revealed that patients with combined HMGB1/
VEGF-C negative expression had the best survival rates,
whereas patients with positive expression of both markers
had the worst survival rates. Those with abnormal expres-
sion of either VEGF-C or HMGB1 had an intermediate
survival rate (Figure 4).Discussion
In the present study, we provide the first evidence that
coexpression of HMGB1 and VEGF-C is associated with
aggressive biological behavior and poor prognosis in a
large series of human GCs and is a valuable prognostic
marker.
HMGB1, the focus of many recent cancer studies, plays a
critical role in cancer development, progression, and metas-
tasis through its pro-angiogenic and pro-lymphangiogenic
functions [18]. Consistent with other studies, the HMGB1
protein was highly expressed in GC samples. We also ob-
served that the positive staining signal was mainly localized
Figure 4 Kaplan-Meier plots for the cumulative 5-year survival of patients with gastric cancer (GC) after radical resection, stratified
according to vascular endothelial growth factor C (VEGF-C) and high-mobility group box 1 (HMGB1) expression status. Patients who
had tumors with combined HMGB1 and VEGF-C expression had significantly poorer prognosis than other patients (P<0.001, log-rank test).
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and stroma, in accordance with its biological function.
Hypoxia results in necrotic or damage-induced cell death
within the tumor when the growing tumor exceeds the
capacity of the existing vasculature. HMGB1 not only
activates vascular endothelial cell proliferation and
neovascularization through the HMGB1-RAGE pathway,
it can also stimulate inflammation [21]. Damaged or nec-
rotic cells can actively secrete or passively release HMGB1
into the extracellular milieu. The constant release of the
pro-inflammatory cytokine HMGB1 from necrotic tumor
cells creates a microenvironment similar to chronic
inflammation and contributes to the development of
epithelial malignancies [22]. Furthermore, the rate of
HMGB1 expression (48.80% of 166) is within the range
of previously reported data [8-12]. Moreover, we observed
that HMGB1 expression was closely correlated with TNM
stage, nodal status, and survival rate but not with age,
gender, or pathological type, as reported previously [8-12].
Controversially, we did not observe any significant differ-
ences in HMGB1 expression between well-differentiated
tumors and poorly differentiated ones, similar to the
results obtained by Hao et al., in which no correlation
between HMGB1 expression and tumor differentiation
was observed [23]. Further studies of HMGB1 expression
in GC and its function are needed.As expected, the correlation of HMGB1 expression
with GC prognosis is in accordance with most of the
findings of previous studies. HMGB1 expression has
been reported to be significantly associated with tumor
invasion, lymph node metastasis, distant metastasis, and
Duke’s stage and inversely associated with overall survival
in human colorectal carcinoma [10]. HMGB1 has been
shown to be an independent prognostic factor for patients
with squamouscell carcinoma of the head and neck [12],
and its overexpression also plays a role in the progression
of nasopharyngeal carcinoma (NPC) and is correlated with
a poor clinical outcome [11]. Serum HMGB1 is closely
associated with the clinical and pathological features of
GC and appears to be a useful serological biomarker for
early diagnosis as well as the evaluation of tumorigenesis,
stage, and prognosis in GC [13]. Regarding the potential
mechanism, Ohmori et al. demonstrated that HMGB1
enhances the proliferation, motility, invasion, and survival
of cancer cells, induces apoptosis of macrophages, and
suppresses the host anti-cancer immune system [24].
However, several studies differ from our conclusion. Bao
et al. concluded that there was no significant association
between HMGB1 expression and invasion depth, tumor
stage, and lymph node metastases. Curiously, their results
suggested that overexpression of HMGB1 was positively
correlated with patient prognosis after curative resection
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the prognosis of the low HMGB1 group was significantly
poorer than that of the high HMGB1 group in GC [8].
Similarly, Jiao et al. proposed that HMGB1 could function
as a tumor suppressor and radiosensitizer in breast cancer
[25] because oxidized HMGB1 increased the cytotoxicity
of these agents and induced apoptosis via the mitochon-
drial pathway or the caspase-9/-3 intrinsic pathway [26].
Furthermore, HMGB1 plays a critical role in tumor im-
munology. The interaction of the HMGB1 protein released
from dying tumor cells with Toll-like receptor 4 on den-
dritic cells is required for the crosspresentation of
tumor antigens and the promotion of tumor-specific
cytotoxic Tcell responses [27,28], which are selectively
involved in the crosspriming of anti-tumor T lymphocytes
in vivo [29,30]. This discordance may be due to the various
tumor types, intricate microenvironments, and different
responses to follow-up treatment in these studies. Further
study of the underlying mechanism of this discordance is a
worthwhile and beneficial avenue to elucidate the precise
role of HMGB1 in tumorigenesis.
VEGF-C is a classic specific growth factor of the lymph-
atic system that is also known to play several roles in tumor
growth and metastasis to lymph nodes and distant organs.
VEGF-C may induce angiogenesis and lymphangiogenesis
in malignant tumors [31,32]. Metastasis to regional lymph
nodes and distant organs through the expression of
VEGF-C has been identified in several cancers such as
colon cancer, prostate cancer, and gastric cancer [16,33-38].
Similarly, in our study, expression of VEGF-C was signifi-
cantly associated with TNM stage, nodal status, and poorer
overall survival [39-45].
Whether HMGB1 and VEGF-C act independently or
cooperatively to increase the malignant potential of GC
is not clear. We verified the high correlation between
these two markers in GC tissues and found that HMGB1
could increase VEGF-C secretion in GC cells (Figure 2).
We also demonstrated that HMGB1 could upregulate
VEGF-C secretion in GC cell lines, suggesting that HMGB1
may enhance the invasion ability of tumor cells, at least
in part, through VEGF-C-related pathways [17,20]. As
expected, Kaplan-Meier survival analysis indicated that
patients with expression of both markers had the
poorest prognoses when compared to all other groups.
Correspondingly, individuals negative for both markers
displayed the longest survival, while patients expressing a
single marker had intermediate survival rates (Figure 4).
Therefore, assessment of HMGB1 and VEGF-C in pre-
operative biopsies may assist in the stratification of GC
patients according to different optimized treatment proto-
cols, such as adjuvant radical or chemotherapy.
The application of molecular diagnosis can be beneficial
for the earlier and more accurate identification of cancer
prognosis or grade of malignancy, thus offering rapid andefficient therapy [46]. Accumulating evidence suggests
that HMGB1 and VEGF-C are useful adjunct markers
for traditional prognostication indices [9-12,39-45]. In
this study, we further confirmed the predictive value of
the molecular approach and verified the benefit by
simultaneously evaluating the expression of HMGB1
and VEGF-C (hazard ratio 2.78, P = 0.0162). Nevertheless,
the mechanism by which coexpression of HMGB1 and
VEGF-C promotes GC progress and metastasis needs to
be further investigated.
Conclusions
HMGB1 expression is dysregulated in GC and is signifi-
cantly correlated with several clinicopathological character-
istics, as is VEGF-C expression. The combined evaluation
of HMGB1 and VEGF-C expression in GC tissues facili-
tates the prediction of clinical prognosis for patients with
GCwho are surgically treated. Double-positive expression
of HMGB1 and VEGF-C is an independent prognostic
factor for survival in patients with GC and a distinguishing
factor for the subgroup of patients with the worst prognosis.
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